#191FUZKK selection 101–300
Can-Fite BioPharma
Israel · Israel
Oncology / ADC / high-potencyFinished dosage forms and small molecules
Manufacturing profile
- Country
- Israel
- Regulatory region
- Israel
- ISO
- ISR
Selection basis
The company is placed in positions 101–300 as a manufacturer, biotechnology company, generics player or CDMO with practical relevance to the FUZKK utility catalog.
The Top 300 is a FUZKK atlas priority rather than a single official revenue table. The mapping does not claim actual use of FUZKK, a specific installed equipment model or a product not confirmed by the public company profile.
Representative manufacturing and QC chain
- 1Contained dispensing and high-potency handling
- 2Chemical synthesis or biologic upstream
- 3Purification and formulation
- 4HPLC/LC-MS/CE and potency analytics
- 5Controlled fill-finish, cleaning and release evidence
- 6Raw-material receipt and identification
- 7Dispensing, blending and granulation
- 8Tableting, encapsulation or solution preparation
- 9Packaging and labelling
Relevant FUZKK packages
Product/API utilities
Lumex — instrumental QC
LabEx — laboratory QC
Assay & Impurity HPLC Quality CheckerLC-MS Confirmation Quality CheckerSterility Test Membrane Filtration Quality CheckerResidual Solvents GC Quality CheckerWater Content KF Quality CheckerElemental Impurities ICP Quality CheckerContent Uniformity Quality CheckerDissolution Apparatus 1 & 2 Quality CheckerStability Condition Monitoring Quality Checker
Medical Devices — equipment and software lifecycle
Suggested first pilot
- Confirm one real product, method or recurring QC review.
- Record the instrument, export format and current specification.
- Select 3–7 utilities from the map above.
- Run a PASS/FAIL sample and agree the expected output.
- After user validation, expand to other products and sites.
Mapping boundary
The Top 300 is a FUZKK atlas priority rather than a single official revenue table. The mapping does not claim actual use of FUZKK, a specific installed equipment model or a product not confirmed by the public company profile.
Methodology